Robert B Bazemore
CIK 1620152 · President & CEO · last filed 2026-06-18
Robert B Bazemore is a President & CEO who has filed 46 SEC Form 4 insider transactions across 7 companies since 2014. The most recent filing, for ARDX, was dated Jun 18, 2026. Across all open-market trades the lifetime net is −$934.5K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $355.2K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$355.2K
7
46
-$934.5K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ARDX | Director | 68,006 | $5.08 | $345.8K | $0 | 11 | 2026-06-18 |
| NUVB | Director | — | $6.69 | — | $0 | 1 | 2026-05-26 |
| AKTX | Director | 1,116 | $8.43 | $9.4K | $0 | 4 | 2025-12-18 |
| Nuvation Bio Inc. (NUVB.WS) Delisted | Director | 5,000 | $0.01 | $26 | $49.9K | 8 | 2025-05-23 |
| Epizyme, Inc. (EPZM) Delisted | President & CEO | 322,626 | $1.47 | $474.3K | -$984.4K | 16 | 2021-03-29 |
| Neon Therapeutics, Inc. (NTGN) Delisted | Director | — | — | — | $0 | 3 | 2020-05-06 |
| SYNAGEVA BIOPHARMA CORP (GEVA) Delisted | Chief Operating Officer | 0 | — | — | $0 | 3 | 2015-06-23 |
Recent Filings
46 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-18 | ARDX | Grant (A) | +26,455 | $0 | EDGAR |
| 2026-05-26 | NUVB | Grant (A) | — | $0 | EDGAR |
| 2025-12-18 | AKTX | Buy (P) | — | $0 | EDGAR |
| 2025-06-23 | ARDX | Grant (A) | +41,551 | $0 | EDGAR |
| 2025-05-23 | Nuvation Bio Inc. (NUVB.WS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-03-24 | AKTX | Grant (A) | — | $0 | EDGAR |
| 2025-03-10 | AKTX | Grant (A) | +44,642 | $50.0K | EDGAR |
| 2024-09-18 | AKTX | Grant (A) | — | $0 | EDGAR |
| 2024-09-05 | Nuvation Bio Inc. (NUVB.WS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-06-17 | ARDX | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.